Neuromyelitis optica (NMO) is an autoimmune inflammatory disease of the central nervous system that causes demyelination and neuron loss, mainly affecting optic nerves and spinal cord. While major advances have been made in understanding NMO pathogenesis mechanisms, including the causal role of immunoglobulin G autoantibodies against astrocyte water channel aquaporin-4 (called AQP4-IgG), there remain unknowns in pathogenesis mechanisms of NMO optic neuritis, in part because of lack of suitable animal models, and unmet needs in developing safe and effective therapies for NMO optic neuritis to prevent vision loss. This renewal application builds on discoveries made by our lab on NMO pathogenesis mechanisms, animal models and therapeutics.
In Aim 1, rat models of NMO optic neuritis will be advanced to study pathogenesis mechanisms and test therapeutics. Robust models of NMO optic neuritis will be developed in AQP4-IgG `seropositive' rats, using, as needed, newly generated CD59-/- rats, NMO `superantibodies', and blood-brain barrier permeabilization by high-frequency focused ultrasound. The hypothesis will be tested that passive transfer of AQP4-IgG alone is sufficient to cause NMO optic neuritis. Also, building on advances in NMO T cell biology and our newly generated AQP4-/- rats, the hypothesis will be tested that AQP4-sensitized T cells initiate and amplify NMO optic neuritis in AQP4-IgG seropositive rats.
Aim 2 will test a novel `bystander' mechanism for tissue injury in NMO in which activated soluble complement components produced by AQP4-IgG binding to AQP4 on astrocytes injure nearby oligodendrocytes, providing a potential explanation for the early demyelination in NMO. Utilizing novel models and imaging methods, the hypothesis will be tested that bystander injury is a general pathogenesis mechanism in NMO, not only for complement-dependent oligodendrocyte injury, but also for microvascular injury.
Aim 3 will advance non-immunosuppressive therapies for NMO optic neuritis. Our lab introduced novel NMO therapies targeting AQP4-IgG and its binding to AQP4, the classical complement pathway, granulocytes and remyelination, including an engineered high-affinity anti- AQP4 antibody (`aquaporumab'). We propose to develop `second-generation aquaporumabs' by conjugating an affinity-matured anti-AQP4 antibody with a complement inhibitor such as CD59, thereby targeting a protective molecule exactly where it is needed, effectively boosting the efficacy of aquaporumab and overcoming limitations on affinity and AQP4 binding site saturation. Also, building on recent work, we will prioritize and test drug candidates for remyelination in NMO optic neuritis. The goal is to advance safe and effective non-immunosuppressive drug(s) to preserve vision in NMO optic neuritis.
Neuromyelitis optica (NMO) is an autoimmune inflammatory disease of the central nervous system that causes demyelination and neuron loss, mainly affecting optic nerves and spinal cord. The proposed research will determine the cellular and immune mechanisms responsible for NMO optic neuritis, and advance novel non- immunosuppressive therapies for NMO.
Showing the most recent 10 out of 259 publications
